Astec LifeSciences Q1FY26: Loss Narrows to ₹33 Cr, Revenue Up 31% YoY

Mumbai, July 28, 2025 — Astec LifeSciences Ltd (BSE: 533138, NSE: ASTEC) reported improved financials for Q1 FY26, with consolidated revenue rising to an estimated ₹90–120 crore—up from ₹70.3 crore in Q1 FY25. The company narrowed its net loss from ₹16.1 crore in Q4 FY25, driven by better volumes, an improved product mix – and early momentum in CDMO and enterprise segments.

To strengthen its balance sheet, Astec’s board approved a ₹250 crore rights issue, boosting investor sentiment. Moody’s-India Ratings maintained a stable AA – outlook, reflecting confidence in the firm’s recovery path. Despite remaining in a loss, Astec shows steady progress toward profitability.

Consolidated Financial Highlights (₹ in Lakh)

For the quarter ended June 30, 2025 (Q1FY26), the company reported a significant year-on-year improvement in financial performance, despite sequential moderation. Revenue from operations rose by 31.3% YoY to ₹9,108.21 lakh, up from ₹6,937.25 lakh in Q1FY25. However, on a quarter-on-quarter (QoQ) basis, revenue declined by 23.8%, down from ₹11,952.70 lakh in Q4FY25, reflecting typical seasonal softness.

Total income also grew by 30.3% YoY to ₹9,158.86 lakh, compared to ₹7,029.62 lakh in the same period last year, but declined 23.9% sequentially. EBITDA loss before tax narrowed sharply to ₹3,301.75 lakh in Q1FY26 from ₹6,163.94 lakh in Q1FY25, showing a 46.4% improvement. However, it widened compared to the loss of ₹1,566.10 lakh in Q4FY25.

The company’s net loss narrowed to ₹3,302.69 lakh (₹33.02 crore) in Q1FY26 from ₹3,971.54 lakh in Q1FY25, reflecting a 16.9% YoY reduction. On a QoQ basis, however, the net loss more than doubled from ₹1,607.90 lakh in Q4FY25, primarily due to the seasonal impact. Earnings per share (EPS) stood at ₹(16.85) for the quarter, better than ₹(20.26) a year ago but weaker than ₹(8.20) in the preceding quarter.

Standalone Performance Snapshot

On a standalone basis, revenue from operations came in at ₹9,108.21 lakh, up 31.3% YoY. The net loss stood at ₹3,305.64 lakh, improving from ₹3,973.69 lakh in Q1FY25. The total comprehensive loss also narrowed to ₹3,300.00 lakh from ₹3,974.06 lakh. EPS improved to ₹(16.86)** from ₹(20.26) in the same period last year. Overall, despite a seasonal dip in performance from Q4, the company delivered a solid year-on-year recovery, driven by growing operational scale and improved cost controls.

Stock Performance

On July 28, 2025, Astec LifeSciences Ltd closed at ₹838.80, down ₹61.35 or 6.82%. The stock opened at ₹903.60, touched a high of ₹925.00 and a low of ₹833.60 during the day.

Rights Issue Update

The Board reiterated the terms of the ₹249.35 crore Rights Issue:

• 28,01,673 shares at ₹890 per share
• Entitlement Ratio: 1:7
• Record Date: July 4, 2025
• Issue Period: July 14 – July 28, 2025

Management Commentary

Managing Director Burjis Godrej stated, “We are focused on cost rationalisation and efficient working capital deployment as we execute our turnaround strategy. The improved revenue traction this quarter validates our product demand pipeline.”

Auditor’s Review

BSR & Co. LLP issued an unmodified limited review report for both standalone and consolidated results, confirming compliance with Ind AS and SEBI regulations.

About Astec LifeSciences Ltd

Astec LifeSciences Ltd, a part of the Godrej Group and listed on both BSE and NSE, operates in the agrochemicals sector with a strong focus on fungicides and contract manufacturing for leading global clients. The company’s subsidiaries include Behram Chemicals Pvt Ltd and Comercializadora Agricola Agroastrachem Cia Ltda, enhancing its domestic and international footprint in crop protection solutions.

REF:https://nsearchives.nseindia.com/corporate/ASTEC_28072025150144_BSENSEBMOUTCOME.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations